Definition

A personalized cancer vaccine (PCV) consisting of mRNA encoding a patient’s tumor-specific neoantigens, with potential immunomodulatory and antineoplastic activities. The cells from the patient’s tumor are analyzed, and genetic sequencing is used to identify neoantigens that may elicit the strongest immune response in the patient. The sequences encoding these neoantigens are transcribed and loaded onto a single mRNA molecule. Upon administration of neoantigen mRNA PCV SW1115C3, the mRNA is taken up by and translated into the desired neoantigens in the patient’s antigen-presenting cells (APCs), primarily dendritic cells (DCs), and presented by major histocompatibility complex (MHC) molecules on the surface of the APCs. This may activate tumor antigen-specific T-cells to kill cancer cells expressing these neoantigens.